Phathom Pharmaceuticals
PHAT
114 hedge funds and large institutions have $588M invested in Phathom Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 40 increasing their positions, 35 reducing their positions, and 16 closing their positions.
17% more capital invested
Capital invested by funds: $504M → $588M (+$83.8M)
14% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 35
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
0% less ownership
Funds ownership: 94.74% → 94.74% (-0%)
3% less funds holding
Funds holding: 117 → 114 (-3)
18% less call options, than puts
Call options by funds: $811K | Put options by funds: $991K
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MVM
Medicxi Ventures Management
St. Helier,
Jersey
|
+$31.5M |
| 2 |
Jennison Associates
New York
|
+$14M |
| 3 |
PBM
Propel Bio Management
Los Angeles,
California
|
+$3.63M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
+$3.44M |
| 5 |
6CM
683 Capital Management
New York
|
+$3.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TPC
Takeda Pharmaceutical Company
Tokyo,
Japan
|
-$36.6M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$4.86M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$4.5M |
| 4 |
NM
Newtyn Management
New York
|
-$4.09M |
| 5 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$3.72M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AG
126
Algert Global
San Francisco,
California
| – | -$136K | -14,920 | Closed |
|
|
A
127
AlphaQuest
New York
| – | -$20.1K | -2,205 | Closed |
|
128
Group One Trading
Chicago,
Illinois
| – | -$13.1K | -1,545 | Closed |
|
|
TWM
129
Tradition Wealth Management
Edina,
Minnesota
| – | -$5K | -500 | Closed |
|
130
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$34 | +4 | New |
|
PHAT Hedge Fund Activity: Q1 2024 in Review
114 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q1 2024, worth a combined $588M — up 17% from $504M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of PHAT and 13 opened new positions — a net loss of 3 holders — while 35 trimmed existing stakes and 40 added.
The largest buyer was Medicxi Ventures Management, adding an estimated $31.5M. The largest seller was Takeda Pharmaceutical Company, cutting an estimated $36.6M.
- 114 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q1 2024, down from 117 in Q4 2023.
- Funds reported $588M of Phathom Pharmaceuticals stock for Q1 2024, up 17% quarter-over-quarter.
- 13 funds opened new Phathom Pharmaceuticals positions in Q1 2024 and 16 closed out, a net change of -3 holders.
- The largest Phathom Pharmaceuticals buyer in Q1 2024 was Medicxi Ventures Management, an estimated $31.5M added.
- The largest Phathom Pharmaceuticals seller in Q1 2024 was Takeda Pharmaceutical Company, an estimated $36.6M sold.
Based on aggregated 13F filings for Q1 2024.